Developing effective treatments for neurological diseases is a big challenge in medicine. But here come UCB and Evotec with a new partnership that could help those suffering from epilepsy and Parkinson’s.
UCB is a Biotech from Brussels that focuses on neurological and immune diseases. The company has multiple products on the market, including an antibody drug for arthritis and Chron’s disease: Cimzia (certolizumab pegol).
Evotec, a German company with top-level partners, has just signed a three-year agreement to support UCB’s drug discovery. The main focus will be disorders of the Central Nervous System (CNS). Although no more details are given, it will likely target epilepsy and Parkinson’s, for which it already has drugs in clinical development.
Epilepsy affects 50 million people globally and although it can be safely managed in most patients, 30% of cases are resistant to drugs. One of the most interesting drugs in UCB’s pipelines is therefore UCB0942 (PPSI), which is in Phase II trials for drug-resistant epilepsy. In this area,